Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) rose 6.8% during mid-day trading on Thursday following a better than expected earnings announcement. The company traded as high as $1.51 and last traded at $1.36, with a volume of 765,091 shares traded. The stock had previously closed at $1.46.

The biopharmaceutical company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.09) by $1.12.

ANTH has been the subject of several research analyst reports. Zacks Investment Research downgraded Anthera Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 8th. ValuEngine downgraded Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Jefferies Group LLC reissued a “hold” rating and set a $2.25 target price on shares of Anthera Pharmaceuticals in a research note on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $10.21.

A number of hedge funds have recently made changes to their positions in ANTH. UBS Group AG boosted its stake in shares of Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares during the last quarter. Finally, Sabby Management LLC boosted its stake in shares of Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares during the last quarter.

The company’s market cap is $14.11 million. The company’s 50 day moving average is $1.53 and its 200 day moving average is $1.13.

WARNING: “Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Stock Price Up -6.8% Following Strong Earnings” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/10/anthera-pharmaceuticals-inc-nasdaqanth-stock-price-up-6-8-following-strong-earnings.html.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.